As artificial intelligence, medical imaging, precision machinery, sensing technologies, and automatic control continue to converge, medical robots are rapidly evolving from conventional mechanically assisted devices into intelligent medical platforms integrating perception, planning, navigation, execution, and feedback capabilities. Their applications are gradually expanding across a wide range of medical scenarios, including surgery, rehabilitation, diagnosis and treatment assistance, and hospital services. Meanwhile, the medical robotics industry value chain is evolving from a traditional equipment manufacturing model toward an integrated ecosystem driven by collaboration across core components, platform systems, clinical applications, and data feedback. Product competition is also extending beyond standalone hardware performance to encompass software algorithms, consumables, services, and platform capabilities.
The 2026 Blue Book on Global Medical Robots Industry Development provides a systematic overview of the medical robots industry, covering industry development, policy evolution, capital market dynamics, international expansion trends, and case studies of representative companies. It also offers an in-depth examination of ten major segments: laparoscopic surgical robots, orthopedic surgical robots, natural orifice surgical robots, neurosurgical robots, vascular interventional robots, dental robots, percutaneous puncture robots, ablation robots, hair transplantation robots, and rehabilitation robots.
From a policy perspective, China's support for medical robotics has gradually expanded from core technology research and development to key stages of industrial commercialization, including high-end medical equipment innovation, product registration, equipment procurement and deployment, medical service pricing, and medical insurance reimbursement. This evolving policy framework provides a more comprehensive institutional environment for the clinical translation of innovative products and the substitution of imported products with domestically developed alternatives. At the same time, Chinese medical robotics companies are accelerating their international expansion. Their overseas business models are evolving from an initial focus on product registration and distributor-led sales toward more comprehensive strategies encompassing overseas clinical validation, physician training, local distribution networks, and after-sales service infrastructure. Accordingly, the criteria for evaluating global competitiveness are shifting from the number of overseas regulatory approvals obtained to the ability to achieve sustained clinical adoption and long-term commercial operations.
Looking ahead, medical robotics is expected to advance toward greater precision, minimally invasive procedures, intelligence, platform integration, and globalization. Artificial intelligence and multimodal sensing technologies will enhance robots' ability to understand complex clinical environments and support clinical decision-making. The role of robotics in clinical procedures is also expected to expand beyond navigation, positioning, and mechanical assistance toward more advanced procedural execution and human–robot collaboration. Meanwhile, the full-lifecycle business model integrating equipment, consumables, software, and services will continue to mature. Clinical value, reimbursement mechanisms, and the ability to achieve large-scale clinical adoption will become key drivers of the industry's next phase of growth.
